David Dadiomov, PharmD, BCPP, joined the faculty of the Titus Department of Clinical Pharmacy as clinical assistant professor of pharmacy practice.
He came to the USC School of Pharmacy from Miami, Florida, where he served as assistant professor at Larkin University College of Pharmacy, coordinating and teaching courses on the pathophysiology and treatment of various diseases and disorders. He also served as clinical psychiatric specialist at Larkin Community Hospital.
He received his PharmD from the University of Michigan College of Pharmacy. He completed his PGY1 Pharmacy residency at Michigan Medicine, and his PGY2 Psychiatric Pharmacy residency at UCSD Health. He holds board certification in psychiatric pharmacy.
David Dadiomov serves as the clinical coordinator for the Whole Person Care Clinical Pharmacy Program. This collaboration with LA County Department of Health Services, Department of Mental Health, and Correctional Health Services aims to improve the access and quality of care to LA County's most marginalized patients (homeless, re-entry, mental health, substance use, and medical high risk patients).
Areas of Expertise (5)
Substance Use Disorders
University of Michigan College of Pharmacy: Pharm.D.
Michigan Medicine: PGY1, Pharmacy Practice
UC San Diego Health: PGY2, Psychiatric Pharmacy
Selected Media Appearances (1)
Dadiomov Joins Faculty
David Dadiomov, PharmD, BCPP, has joined the faculty of the Titus Department of Clinical Pharmacy as clinical assistant professor of pharmacy practice.
Selected Event Appearances (1)
Long Acting Medications for Justice-Involved Populations
California Access Coalition Webinar
Selected Articles (7)
Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemicAmerican Journal of Health System Pharmacy
Alyssa Peckham, Jennifer Ball, Michelle D Colvard, David Dadiomov, Lucas G Hill, Stephanie D Nichols, Kimberly Tallian, Daniel J Ventricelli, Tran H Tran
Purpose: Strategies for deploying clinical pharmacists to increase access to buprenorphine in inpatient, outpatient and transitional care, and community practice settings are described. Summary: Access to medications for opioid use disorder (MOUD) is essential, but patients face many barriers when pursuing treatment and MOUD. The coronavirus disease 2019 (COVID-19) pandemic has compounded the opioid crisis and worsened outcomes by introducing new barriers to MOUD access. Many strategies to ensure continued access to MOUD have been described, but the role of leveraging pharmacists during the opioid/COVID-19 syndemic to improve medication access and outcomes remains underappreciated. Pharmacists, while both qualified and capable of liberalizing access to all forms of MOUD, may have the strongest impact by increasing access to buprenorphine. Herein we present progressive strategies to maintain and extend buprenorphine access for patients with OUD through deployment of clinical pharmacists, particularly in the context of the COVID-19 pandemic, during which access may be further restricted. Conclusion: Leveraging pharmacists to extend access to MOUD, particularly buprenorphine, remains an underutilized strategy that should be implemented, particularly during the concurrent COVID-19 global pandemic.
Safety of Repeated Administration of Parenteral Ketamine for DepressionPharmaceuticals
David Feifel, David Dadiomov, Kelly Lee
The objective of this study was to investigate the safety of repeated parenteral ketamine for depression. An electronic survey inquiring about the frequency of adverse events was distributed to providers of parenteral ketamine for depression. In addition, the investigators conducted a search of published studies describing six or more repeated parenteral ketamine treatments administered to individuals for depression, and extracted reported adverse events. The survey was sent to 69 providers, of which 36 responded (52% response rate); after eliminating those that were incomplete, 27 were included in the analysis. The providers in the analysis collectively reported treating 6630 patients with parenteral ketamine for depression, one-third of whom received more than 10 treatments. Only 0.7% of patients experienced an adverse effect that required discontinuation of ketamine. Psychological distress during the treatment was the most frequent cause. Other adverse events were extremely rare (such as bladder dysfunction (0.1%), cognitive decline (0.03%) and psychotic symptoms (0.03%)). Among the 20 published reports of repeated parenteral ketamine treatments, rates of significant adverse events resulting in discontinuation were low (1.2%). The rate of adverse effects reported in the survey and the published literature is low, and suggests that long-term treatment of depression with ketamine is reasonably safe.
Chapter 3: Laboratory Testing for Substance Use DisordersAbsolute Addiction Psychiatry Review
This book serves as a tool for general psychiatrists, medical students, residents, and fellows looking for a clinically relevant and high-yield overview of addiction psychiatry in preparation for their board exams – or for everyday clinical practice. Written by expert educators in addiction psychiatry, the text is organized by substances misused and populations affected. This book serves as both a primary learning tool for those new to the field, as well as a reference for those working in addiction treatment. Each chapter begins with summaries of high yield clinical pearls, followed by general information including treatment, and then ends with accompanying board-style review questions. The scope includes understanding substances of misuse and substance use disorders (SUDs), how to evaluate, diagnose, and monitor SUDs, how to treat SUDs both pharmacologically and behaviorally, and critical information for specific populations of patients.
Therapeutic Drug Monitoring of AntipsychoticsCurrent Psychiatry
Savvy Psychopharmacology Column in Current Psychiatry
Dissociating the Clinical Role and Economic Value of Intranasal EsketamineJournal of Managed Care & Specialty Pharmacy
Perspective on Value: Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
The effects of ketamine on suicidality across various formulations and study settingsMental Health Clinician
David Dadiomov and Kelly Lee
2019 Suicidality and self-injurious behavior afflict patients with a wide variety of psychiatric illnesses. Currently, there are few pharmacologic treatments for suicidality and self-injurious behavior and none that treat these conditions emergently. Recently, ketamine has demonstrated efficacy in treating both depression and acute suicidal ideation. An increasing usage of ketamine, of a variety of formulations, has been studied for these indications. This article reviews the evidence for use of ketamine in self-injurious behavior and suicidality.
Using the LACE Score as a Predictor of Clinical Outcomes in Patients Referred for Inpatient Palliative Care Consultation: A Single-Center ExperienceAmerican Journal of Hospice and Palliative Medicine
David Dadiomov, Patricia Keefer, and Michael A. Smith
2018 Readmissions and death for palliative care patients are common and costly outcomes for hospitals, patients, and/or caregivers. Predicting which patients are likely to be readmitted or die within 30 days would help allocate resources and aid in patient disposition planning. Few factors have been strongly correlated with predicting which patients will be readmitted or die within 30 days of hospital discharge. The LACE (Length of Stay, Acuity of admission, Charlson comorbidity index, Emergency department use) score has been validated in medical/surgical patients; however, it has not been evaluated in the palliative care population.